


Patients with Severe Community Acquired Pneumonia

REMAP-CAP

Does hydrocortisone improve mortality in severe community-acquired pneumonia (CAP)?

International adaptive randomized controlled platform trial

101 sites in 18 countries



HYDROCORTISONE

Intravenous hydrocortisone 50 mg every 6 hours for 7 days:

- No tapering required
- Discontinued at hospital discharge if before 7 days
- 99% (527/533) received at least one dose
- Median duration: 7 days (IQR 4-8)

536 PATIENTS


NO HYDRROCORTISONE

Patient received no corticosteroids

- 23% (28/122) received systemic corticosteroids for clinical indications
- Median duration when used: 4 days (IQR 2-5.3)
- Only 1 patient (0.8%) received full-dose equivalent treatment

122 PATIENTS

90-day All-cause Mortality



OR: 1.56 (95% CI 0.80 – 3.31)

10% probability of superiority and 90% of harm!

Among patients with severe CAP, treatment with a 7-day course of hydrocortisone, compared with no hydrocortisone, appears unlikely to yield a large reduction in mortality. Smaller benefits and possible harm are not excluded